Healthcare / Medical Instruments & SuppliesNYSE American
$0.39
-0.00 (-1.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-2.9M · quality 70.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$34M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-203.4%
↓Gross Margin
71.4%
↑Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-32.7%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.0M · net income $-5.7M · FCF $-2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $9.0M | $9.0M | $8.6M | $9.8M | $8.8M | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-5.7M | $-5.7M | $-4.7M | $-6.9M | $-8.7M | $-6.8M | $-7.3M | $-7.5M | $-7.4M | $-5.2M | $-5.9M | $-5.5M | $-1.7M | $1.5M | $-870306.00 | $-1.5M | $-614508.00 |
| EBITDA | $-5.5M | $-5.5M | $-6.6M | $-7.0M | $-8.7M | $-7.3M | $-7.4M | $-3.9M | $-7.1M | $-4.7M | — | — | — | — | — | — | — |
| EPS | — | — | -0.06 | -0.10 | -0.12 | -0.10 | -0.12 | -0.16 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.08 | -0.05 | — | — |
| Gross Margin | 71.4% | 71.4% | 74.6% | 69.1% | 55.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -63.5% | -63.5% | -78.3% | -72.3% | -100.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -63.8% | -63.8% | -54.6% | -70.5% | -98.9% | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.36 | 0.36 | 0.06 | 0.05 | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.51 | 1.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-2.9M | $-2.9M | $-2.9M | $-5.3M | $-6.0M | $-4.0M | $-7.0M | $-1.8M | $-1.6M | $-1.2M | $-5.4M | — | — | $1.3M | $-54453.00 | $-578197.00 | $-323132.00 |
| Returns | |||||||||||||||||
| ROE | -203.4% | -203.4% | -80.8% | -86.5% | -85.1% | -41.7% | -45.3% | -443.7% | -482.7% | -71.6% | -70.0% | -53.0% | -11.6% | 26.5% | -44.9% | -76.5% | -26.3% |
| Valuation | |||||||||||||||||
| P/B | 11.04 | 11.04 | 13.00 | 5.72 | 3.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 4.0% | 4.0% | -12.2% | 11.6% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | — | — | 40.0% | 16.7% | — | 16.7% | 25.0% | 23.8% | -31.2% | 27.3% | 15.4% | -225.0% | -200.0% | 260.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-58.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → n/d
Residual
-58.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.